Mental health · Boston area, MA
Mental health studies in Boston area, MA
70 recruiting studies have a site in the Boston area. This page includes nearby cities such as Cambridge, Brookline, Newton, Waltham.
70 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Boston, MA + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
ACADIA Pharmaceuticals Inc.
- Location
- Watertown, MA + 23 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Boston, MA + 31 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Boston, MA + 33 other US sites
- Eligibility basics
- Ages 18–74
- Recruiting
SAINT in Postpartum Depression (PPD)
Magnus Medical
- Location
- Worcester, MA + 3 other US sites
- Eligibility basics
- Ages 18–45 · Women only
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Watertown, MA + 41 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Boston, MA + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Boston, MA + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Boston, MA + 18 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals
- Location
- Boston, MA + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Belmont, MA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Transcend Therapeutics
- Location
- Worcester, MA + 36 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Home-Based tDCS Treatment Of Major Depressive Disorder
Sooma Medical Inc
- Location
- Boston, MA
- Eligibility basics
- Ages 22–70
- RecruitingPhase 2
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences, Inc
- Location
- Worcester, MA + 22 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Boston, MA + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of NTX-1472 in Social Anxiety Disorder
Newleos Therapeutics, Inc.
- Location
- Boston, MA + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Monument Therapeutics Limited
- Location
- Boston, MA + 14 other US sites
- Eligibility basics
- Ages 17–30
- RecruitingPhase 2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
atai Therapeutics, Inc.
- Location
- Springfield, MA + 33 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Watertown, MA + 20 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics, Inc.
- Location
- Boston, MA + 31 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
Evaluating the Acceptability, Feasibility and Usability of Various Conversational Data Collection Software
AugMend Health Inc.
- Location
- Cambridge, MA
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Boston, MA + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Axsome Therapeutics, Inc.
- Location
- Boston, MA + 36 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteers
Preventing Depression of Chinese American Adolescents by RRE
Northeastern University
- Location
- Boston, MA
- Eligibility basics
- Ages 14–18
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.